Inge Marie Svane, MD, PhD is Professor in Clinical Cancer Immune Therapy at the University of Copenhagen, Director of National Center for Cancer Immune Therapy (CCIT-DK), Herlev and Gentofte Hospital, and Chief Physician specialized in melanoma at the Department of Oncology at Copenhagen University Hospital, Herlev, Denmark. She is also head of the Clinical Academic Group in Cancer Immunotherapy, Copenhagen Health Sciences Partners.

Inge Marie Svane has 25 years of research experience in cancer immunology and immunotherapy and holds a PhD in basic cancer immunology. She has pioneered the field of cancer immunotherapy in Denmark, building up CCIT-DK, a translational research center in a leading European position. Her focus of expertise is T-cell based adoptive cell therapy and other cellular therapies, cancer vaccines, and immune regulation.

Since 2001 she has initiated around 20 phase I, II, and III immunotherapeutic trials as sponsor. Further, she is national principal investigator on numerous international clinical trials in collaboration with the pharmaceutical industry, primarily within the area of immunotherapy.

Inge Marie Svane is co-founder of IO Biotech, a spinout biotech company from Herlev and Gentofte Hospital and the Capital Region of Denmark aiming to develop immune regulating vaccines for cancer therapy.

Inge Marie Svane has an extensive cooperative network with scientists and clinicians nationally and internationally and is a frequent speaker at national and international meetings, courses, and conferences.

Inge Marie Svane is key opinion leader on cancer immunotherapy, acknowledging the importance of communication to the public, patient associations, and politicians. She actively supports the European cancer patient coalition as scientific committee member in the Immuno-Oncology Academy. She is member of the scientific committee and faculty on Immunotherapy in the European Society for Medical Oncology, ESMO. Further, she is initiator of a national, scientific network, IMMUNONET, member of the European melanoma group, EORTC, and member of the Danish Melanoma Group heading national treatment guidelines and real-world patient registries.

Inge Marie Svane is co-author of more than 240 scientific publications, including papers in Clin Cancer Res, Cancer Res, Blood, Nature, Nature Immunol, Nature Biotech, Lancet Oncol, and Immunology.